News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase II
Milestone Pharmaceuticals Announces Positive Phase 1 Data For MSP-2017; Supports Advancement Into Phase 2 In PSVT Patients 11/24/2014
Synthetic Biologics, Inc. (SYN) Safe-To-Proceed Under IND To Initiate Clinical Trials Of SYN-004 For The Prevention C. Difficile Infection 11/24/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase 2 Study Of The Investigational Drug Abaloparatide In Postmenopausal Women With Osteoporosis 11/24/2014
Genmab, Inc. (GEN.CO) Announces Phase 2 Study Of Daratumumab In Smoldering Multiple Myeloma 11/24/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of REVEAL-1 Trial Results In The British Journal Of Haematology 11/24/2014
Xenetic Biosciences Partner Completes First Patient Cohort In Phase 2 Study With MyeloXen™ For Multiple Sclerosis 11/21/2014
University of Pennsylvania Doses First Patient In Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy 11/21/2014
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Final Analysis Of The Phase II Clinical Study On Elafin In Coronary Artery Bypass Surgery Completed 11/21/2014
Clementia Pharmaceuticals Receives European Medicines Agency Orphan Medicinal Product Designation For Palovarotene For The Treatment Of Fibrodysplasia Ossificans Progressiva 11/21/2014
BioSpecifics Technologies Corporation (BSTC) Announces New Data On XIAFLEX For Peyronie's Disease Presented At SMSNA Scientific Meeting 11/21/2014
Intra-Cellular Therapies, Inc. Announces Additional Results From Phase I/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia 11/21/2014
ChemoCentryx, Inc. (CCXI)'s CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA 11/21/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014
NeoStem, Inc. Provides Further Information Regarding The Design Of The Phase 2 PreSERVE AMI Clinical Trial 11/21/2014
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014
Neurotrope Announces Last Patient Dosed In Phase 2a Clinical Trial Of Bryostatin-1 For Alzheimer's Disease 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
St. Jude Children's Research Hospital Release: Gene Therapy Provides Safe, Long-Term Relief For Patients With Severe Hemophilia B 11/20/2014
DBV Technologies Initiates Phase I/2 Clinical Trial With Viaskin Milk For The Treatment Of Children With Cow's Milk Allergy 11/20/2014
PRANA Biotechnology (PRAN) Release: The Lancet Neurology Publishes Prana's Huntington Disease Trial 11/20/2014
Autifony Therapeutics Announces Initiation Of Phase 2a Study For First-In-Class Drug To Treat Tinnitus 11/20/2014
Neurotrope Announces Last Patient Dosed In Phase 2a Clinical Trial Of Bryostatin-1 For Alzheimer’s Disease 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents STENDRA Data At SMSNA Scientific Meeting 11/20/2014
NeoStem, Inc.'s Stem Cell Therapy Fails Mid-Stage Heart Attack Study 11/19/2014
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica 11/19/2014
Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA For Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3 11/19/2014
Synergy Pharmaceuticals Announces Positive Results Of SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation 11/19/2014
BIND Therapeutics (BIND) Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-Small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium 11/19/2014
Tokai Pharmaceuticals (TKAI) Presents Updated Interim Galeterone ARMOR2 Data Showing Activity In Patients With Castration-Resistant Prostate Cancer (CRPC) Including Those Showing A Variant Form Of Prostate Cancer Resistant To Hormone Therapy 11/19/2014
PTC Therapeutics, Inc. (PTCT) Release: Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA 11/19/2014
Amgen (AMGN) Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 11/19/2014
VGTI Florida To Collaborate With TapImmune Inc. (TPIV) To Advance Targeted Breast And Ovarian Cancer Vaccines Into Phase 2 Clinical Trials 11/19/2014
Omni Bio Pharmaceutical Announces Phase 1/2 Clinical Data Of AAT In Myocardial Infarction At American Heart Association Scientific Session 11/19/2014
Omeros Corporation (OMER) Release: OMS721 Inhibits Thrombus Formation In Sera from aHUS Patients 11/19/2014
UPDATE: Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid(R) Is Well Tolerated And Increases CD4 Counts In People Living With HIV 11/19/2014
MabVax Therapeutics, Inc. And Memorial Sloan-Kettering Cancer Center Report On Potential Use Of Dual-Labeled Antibody To Detect And Guide Surgical Removal Of Pancreatic Cancer 11/19/2014
Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid® Is Safe And Increases CD4 Counts In People Living With HIV 11/18/2014
Trevena, Inc. (TRVN) Announces Positive Top-Line Results From Phase 2a/b Study Of TRV130 In Acute Postoperative Pain 11/18/2014
NeoStem, Inc. Announces Initial Positive Data From Phase 2 Preserve AMI Clinical Trial 11/18/2014
Sarepta Therapeutics (SRPT) Announces First Patient Dosed In Confirmatory Study Of Eteplirsen In Ambulant Patients With Duchenne Muscular Dystrophy 11/18/2014
Juventas Therapeutics, Inc. Presents Phase 2 Data At American Heart Association Scientific Sessions That Shows JVS-100 Is Safe, Potentially Effective In Patients With Critical Limb Ischemia 11/18/2014
Innovative Med Concepts, LLC Release: Novel Fibromyalgia Treatment Shows Promise In Study 11/18/2014
Juno Therapeutics's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA 11/18/2014
ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI 11/18/2014
Galena Biopharma  (GALE) Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 11/18/2014
Levolta Pharmaceuticals Presents Phase 2 Study Results For Potential Osteoarthritis Therapy At American College of Rheumatology Annual Meeting 11/18/2014
Merck & Co. (MRK) Announces Positive Study Investigating The Use Of KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In Patients With Ipilimumab-Refractory Advanced Melanoma 11/17/2014
Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 11/17/2014
NeuroSigma, Inc. Announces Top-Line Findings Of University of California, Los Angeles (UCLA) Phase 2 Clinical Trial Of eTNS For The Treatment Of Depression 11/17/2014
OrthoTrophix Completed Patient Treatments In Part A Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis And Initiated Patient Enrollment For Part B 11/17/2014
AbbVie (ABBV) Presents Results From Study Of ABT-414 In Patients With Glioblastoma Multiforme At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology 11/17/2014
Celldex Therapeutics, Inc. (CLDX) Release: Interim Update From Randomized Phase 2 ReACT Study Of Rindopepimut In Recurrent Bevacizumab-Naive Glioblastoma Demonstrates Statistically Significant Survival Benefit 11/17/2014
Alder Biopharmaceuticals Inc. Release: Data From Phase 2b Clinical Trial Of Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Active Psoriatic Arthritis, To Be Presented At The American College of Rheumatology Annual Meeting 11/17/2014
MedImmune (AZN) Presents Promising New Data In Systemic Lupus At American College of Rheumatology Meeting 11/17/2014
MedImmune (AZN) Presents Positive Phase 2b Data For Mavrilimumab In Rheumatoid Arthritis At American College of Rheumatology Annual Meeting 11/17/2014
DelMar Pharmaceuticals' Promising New Data Support The Potential Of VAL-083 To Meet Significant Unmet Medical Needs In The Treatment Of Glioblastoma Multiforme 11/17/2014
Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial Of Quadrivalent Seasonal Influenza VLP 11/17/2014
ChemoCentryx, Inc. (CCXI)'s Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 11/17/2014
Ardelyx Inc. (ARDX)'s Tenapanor Reduces Phosphorus Absorption And Protects Against Vascular Calcification In Preclinical In Vivo Model Of Chronic Kidney Disease 11/17/2014
Naurex Inc. Release: Data Presented At Society For Neuroscience Demonstrates That Naurex's GLYX-13 Enhances Synaptic Plasticity Through NMDA Receptor Modulation 11/17/2014
Puma Biotechnology (PBYI)'s Cancer Drug Neratinib Fails Mid-Stage Study 11/14/2014
Alnylam Pharmaceuticals (ALNY) Reports Positive Initial Phase 2 Data With Revusiran 11/14/2014
Chimerix, Inc. (CMRX)'s Brincidofovir Antiviral To Be Tested In West African Ebola Trial 11/14/2014
Chimerix, Inc. (CMRX)'s Brincidofovir Selected For Use In Ebola Clinical Trial In West Africa By International Consortium 11/14/2014
Puma Biotechnology (PBYI) Announces Positive Top Line Results From PB272 Phase 2 Trial In HER2 Positive Metastatic Breast Cancer (Nefertt Trial) 11/14/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Presents Updated ICT-107 Phase 2 Data at the Society for Neuro-Oncology Annual Meeting 2014 11/14/2014
Viralytics Ltd (VLA.AX) Receives UK Approval To Commence Clinical Trial Of CAVATAK In Bladder Cancer 11/14/2014
AbbVie (ABBV)'s Hepatitis C Drug Cures 97 Percent In Phase 2 Transplant Patients Study 11/13/2014
Mesoblast Limited (MSB.AX)'s Phase 2 Trial Results In Chronic Low Back Pain Presented At North American Spine Society Annual Meeting 11/13/2014
Galmed Pharmaceuticals Announces First Administration Of Aramchol In Its Phase 2a Trial For The Treatment Of Cholesterol Gallstones 11/13/2014
ProLynx Awarded NSF Phase 2 Grant For Controlled Drug Release From And Degradation Of Hydrogel 11/13/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In TIGER-1 Study 11/13/2014
GenKyoTex S.A. Completes Enrollment Into Phase 2 Trial Of NOX1&4 Inhibitor GKT137831 In Diabetic Nephropathy 11/13/2014
La Jolla Pharmaceutical Company (LJPC) Release: Results From Phase 2 Study Of GCS-100 In Chronic Kidney Disease Being Presented At American Society of Nephrology Kidney Week 11/13/2014
Neuren Pharmaceuticals Limited's NNZ-2566 Successful In Demonstrating Clinical Benefit In Rett Syndrome Phase 2 Trial 11/13/2014
VBL Therapeutics (VBLX) To Present Interim Phase 2 Data From VB-111 In Recurrent Glioblastoma At 19th Annual Scientific Meeting Of The Society For Neuro-Oncology (SNO) 11/13/2014
Vascular Pharmaceuticals Initiates Phase 2 Clinical Trial Of VPI-2690B For Diabetic Nephropathy 11/13/2014
Regeneron (REGN), Sanofi (SAN.PA)'s Dual-Action Biotech Asthma Drug Performs Well In Key Test 11/12/2014
AbbVie (ABBV) To Present Results From Studies In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) And Liver Transplant Recipients (CORAL-I) At The Liver Meeting® 2014 11/12/2014
CSL Limited (CMXHF.PK) Launches AEGIS-I, A Phase 2b Clinical Study Of CSL112, A Novel Apolipoprotein A-I Infusion Therapy Designed To Rapidly Remove Cholesterol From Arteries And Stabilize Plaque 11/12/2014
Animal Study Confirms Results Of ChromaDex, Inc. Human Clinical Study On Weight Loss With Pterostilbene 11/12/2014
Galapagos NV (GLPG.BR) Completes Recruitment For Darwin 1 Study With GLPG0634 (Filgotinib) In RA 11/12/2014
Ocular Therapeutix, Inc. (OCUL) Announces Top-Line Results From Phase 2 Sustained Release Dexamethasone Trial For Allergic Conjunctivitis 11/12/2014
Ocular Therapeutix, Inc. (OCUL) Enrolls First Patients In Phase 2b Clinical Trial For Sustained Release Travoprost For The Treatment Of Glaucoma And Ocular Hypertension 11/12/2014
AB Science (AB.PA): The Data And Safety Monitoring Board Recommends The Continuation Of The Phase 2 Study With Masitinib In Advanced Hepatocellular Carcinoma 11/12/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma 11/12/2014
Merck & Co. (MRK)'s Four-Week Hep C Regimen With Gilead Sciences, Inc. (GILD)'s Sovaldi Fails To Deliver 11/11/2014
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Results From Phase 2b Study Of Dupilumab In Patients With Moderate-To-Severe Asthma 11/11/2014
Galena Biopharma  (GALE) Doses First Patient In Phase 2 Clinical Trial With Neuvax(TM) (Nelipepimut-S) In Combination With Herceptin® (Trastuzumab) To Treat High-Risk HER2 3+ Or HER2 Gene-Amplified Breast Cancer Patients 11/11/2014
Enzymotec Initiates Clinical Study Of Vayarin® In Adult ADHD 11/11/2014
Generex Biotechnology Corporation (GNBT) Announces Presentation At The Society For Immunotherapy Of Cancer Demonstrating That Induction Of Antibody Response In Patients Receiving The AE37 Breast Cancer Vaccine Correlates With Reduced Relapse 11/11/2014
Gilead Sciences, Inc. (GILD) Announces Phase 2 Data For Investigational All-Oral Regimen Of Sofosbuvir Plus GS-5816 For The Treatment Of Chronic Hepatitis C 11/11/2014
Merck & Co. (MRK) Announces Results From Phase 2 Study Of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir In Genotype 1 Infected Treatment-Naïve And Difficult-To-Cure Patients 11/11/2014
Patient Enrollment In Cellceutix (CTIX) Phase 2 Clinical Trial Of Brilacidin-OM For Oral Mucositis Targeted To Begin In December 2014 11/11/2014
Kadmon Corporation Researchers Define Importance Of ROCK2 Signaling Pathway In Human Autoimmune Response 11/11/2014
Alnylam Pharmaceuticals (ALNY) Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepatitis Delta Virus (HDV) Infection And ALN-PDL For The Treatment Of Chronic Liver Infections 11/11/2014
Enanta Pharmaceuticals, Inc. Announces Results From TURQUOISE-I Study In Chronic Hepatitis C Patients With HIV-1 Co-Infection And From The CORAL-I Study In Liver Transplant Recipients At The Liver Meeting 2014® 11/11/2014
Enanta Pharmaceuticals, Inc. Announces Results From Phase 2b PEARL-I Study In Genotype 4 Chronic Hepatitis C Patients At The Liver Meeting 2014® 11/11/2014
ArQule, Inc. (ARQL) Reports Positive Phase 2 Tivantinib Prostate Cancer Trial Data 11/10/2014
Intercept Pharmaceuticals (ICPT) Tanks As Liver Drug Needs Safety Review: Investigators 11/10/2014
Achillion Pharmaceuticals, Inc. (ACHN) Reports 100% SVR12 In A Phase 2 Combination Study With ACH-3102 At The Liver Meeting 2014 (American Association for Study of Liver Diseases) 11/10/2014
OXiGENE (OXGN) Announces Presentation Of Phase 2 Data Confirming That Addition Of Fosbretabulin To Bevacizumab Significantly Increases Progression-Free Survival In Recurrent Ovarian Cancer 11/10/2014
Karyopharm Therapeutics (KPTI) Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation 11/10/2014
NeoStem, Inc. Data From Phase 2 Preserve AMI Clinical Trial To Be Presented At American Heart Association Scientific Sessions On November 17 11/10/2014
Intercept Pharmaceuticals (ICPT) Announces Additional Data For OCA In Primary Biliary Cirrhosis 11/10/2014
Merck & Co. (MRK)’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir In Combination With A Nucleotide Inhibitor (C-SWIFT Study) Presented At The Liver Meeting® 11/10/2014
Phase II Clinical Data Presented At SITC Annual Meeting Support Immunotherapeutic Mechanism Of Action Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Liver Cancer 11/10/2014
Intercept Pharmaceuticals (ICPT) Release: FLINT Trial in NASH Published in The Lancet 11/7/2014
Galena Biopharma  (GALE) Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data At The Society For Immunotherapy Of Cancer (SITC) 29th Annual Meeting 11/7/2014
Neuronetrix, Inc. Has Been Selected By Anavex Life Sciences Corp. (AVXL.OB) To Support The Upcoming Phase 2a Clinical Trial For ANAVEX 2-73 11/7/2014
Nuvilex (NVLX) Applies In Australia For The Orphan Drug Designation For Pancreatic Cancer Treatment 11/7/2014
Omeros Corporation (OMER) Announces Positive Data for MASP-2 Inhibitor In Experimental Model Of Stroke 11/6/2014
GlaxoSmithKline (GSK) Discloses Good Efficacy In Psoriasis With GSK2856184 11/6/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reports Improved Response Rates In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia 11/6/2014
Prima Biomed (PRR.AX) Release: CVac Demonstrates Overall Survival Benefit In Second Remission Ovarian Cancer 11/6/2014
Exelixis, Inc. (EXEL) Reports Top-Line Results From A Phase 2 Trial Of Cabozantinib 11/5/2014
Alnylam Pharmaceuticals (ALNY) Completes Phase 2 Enrollment And Initiates Open-Label Extension (OLE) Study With Revusiran (ALN-TTRsc), An Investigational Rnai Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis 11/5/2014
Merck & Co. (MRK) Reports Positive Data From Phase 2b Doravirine Trial 11/4/2014
Alder Biopharmaceuticals Inc. Initiates Phase 2b Clinical Trial Of ALD403 For Preventative Treatment Of Chronic Migraine 11/4/2014
D-Pharm Ltd. Reports First Results From Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 11/4/2014
Transition Therapeutics Inc. (TTH.TO) Reports Findings From Bipolar Disorder Phase 2 Study 11/4/2014
Galena Biopharma  (GALE) To Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data At The Society For The Immunotherapy Of Cancer (SITC) 29th Annual Meeting On Friday, November 7, 2014 11/4/2014
Altor BioScience Corporation Initiates Clinical Development Of Its Novel IL-15 Super Agonist ALT-803 For Relapsed / Refractory Multiple Myeloma Supported By A Newly Awarded Phase 2 SBIR Grant From National Cancer Institute 11/4/2014
Genzyme Corporation (GENZ) Announces Enrollment Of First Patient In Phase II Vatelizumab Trial In Relapsing Remitting Multiple Sclerosis 11/4/2014
VBL Therapeutics (VBLX) To Present Interim Phase 2 Data From VB-111 In Recurrent Glioblastoma At 19th Annual Scientific Meeting Of The Society For Neuro-Oncology (SNO) 11/3/2014
Anavex Life Sciences Corp. (AVXL.OB) Receives Regulatory Approval To Initiate Phase 2a Clinical Trial Of ANAVEX 2-73 And ANAVEX PLUS For Alzheimer's Disease 11/3/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Report Results Of An Investigational Phase 2 Trial Of Lorcaserin Hcl As An Aid For Smoking Cessation 11/3/2014
Promedior Receives Fast Track Designation For PRM-151 For The Treatment Of Myelofibrosis 11/3/2014
Inventiva Receives Positive Opinion On Orphan Drug Designation In The European Union For IVA337 - A Treatment For Systemic Sclerosis (SSc) 11/3/2014
BioLineRx Ltd. Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile 11/3/2014
Targovax Reaches Primary Endpoint For Ongoing Phase 1/2 Clinical Trial Of Pancreatic Cancer RAS Mutation Vaccine CT TG01-01 11/3/2014
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Receives FDA Authorization To Initiate Phase 1/2a Trial Of Embryonic Stem Cell-Derived Opregen® For The Treatment Of The Dry Form Of Age-Related Macular Degeneration 11/3/2014
Bristol-Myers Squibb Company (BMY)'s Opdivo Wows In Phase 2 Lung Cancer Study 10/31/2014
BioLineRx Ltd. Reports Publication In Peer Review Journal Of Results From Previous Phase 1/2 Trial For BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 10/31/2014
Onxeo: Positive Phase 2 Preliminary Results Of Validive® For The Prevention Of Severe Oral Mucositis In Head And Neck Cancer Patients 10/31/2014
BIND Therapeutics (BIND) Announces Availability Of Abstract With Preliminary Data From Phase 2 Study Of BIND-014 In Non-Small Cell Lung Cancer 10/30/2014
Immunomedics, Inc. (IMMU) Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers 10/30/2014
Recro Pharma (REPH) Announces Dosing Of First Patient In Phase 2 REC-14-013 Clinical Trial Of Dex-IN For Treatment Of Acute Pain On Day 1 Following Surgery 10/30/2014
GW Pharmaceuticals Commences Phase 2/3 Clinical Trial Of Epidiolex® As A Potential Treatment For Epilepsy In Dravet Syndrome 10/30/2014
Ultragenyx Pharmaceuticals (RARE) Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia 10/30/2014
Neurocrine Biosciences, Inc. (NBIX) Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia 10/30/2014
AnaMar AB Reports Top-Line Results From Exploratory Phase 2a Study Of AMAP102 And Provides Corporate Update 10/30/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Baxter International, Inc. (BAX)’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy And Tolerability Endpoints In Phase 2/3 Study 10/30/2014
Cara Therapeutics, Inc. (CARA) Touts Positive Data From New Opiod Pain Drug Trial 10/29/2014
Synta Pharmaceuticals (SNTA) Announces Initiation Of I-SPY 2 TRIAL Of Ganetespib In Breast Cancer 10/29/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.)'s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted Into First Patient 10/29/2014
Receptos (RCPT) Soars As Bowel Disorder Drug Meets Phase 2 Goals 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
New Clinical Trial Data: The Scripps Research Institute MS Drug Candidate Also Shows Promise For Ulcerative Colitis 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
Apogenix- Positive Results From APG101 Phase 2 Clinical Trial Published In Clinical Cancer Research 10/28/2014
Moberg Pharma AB (Formerly known as Moberg Derma): First Patient Included In Phase 2 Study Of BUPI, A Novel Topical Formulation For Treatment Of Oral Pain 10/28/2014
Araim Pharmaeuticals Given FDA Fast Track Designation To ARA 290 For The Treatment Of Sarcoidosis-Associated Small Fiber Neuropathy 10/28/2014
Akebia Therapeutics, Inc. (AKBA)'s Lead Drug AKB-6548 Succeeds In Mid-Stage Trial 10/27/2014
Heat Biologics Commences Patient Dosing Of Phase 2 Clinical Study Of Vesigenurtacel-L For The Treatment Of Bladder Cancer 10/27/2014
PTC Therapeutics, Inc. (PTCT) Release: Translarna™ Phase 2b Data Published In Muscle & Nerve 10/27/2014
Burzynski Research Institute Announces FDA Permission To Launch A New Clinical Trial In Diffuse Intrinsic Brainstem Glioma 10/27/2014
Generex Biotechnology Corporation (GNBT) Announces Presentations Correlating Immunological Response With Reduced Recurrence In Phase 2 Study Of AE37 Breast Cancer Vaccine In Patients At The American College of Surgeons 10/27/2014
Ultragenyx Pharmaceuticals (RARE) Granted Orphan Drug Designation For Triheptanoin For The Treatment Of Glucose Transporter Type-1 Deficiency Syndrome 10/27/2014
Sunovion Pharmaceuticals Inc. Announces Dose Ranging Data From Phase 2 Study Of SUN-101 (Glycopyrrolate) Inhalation Solution For Treatment Of Patients With Moderate-To-Severe Chronic Obstructive Pulmonary Disease (COPD) 10/27/2014
Metanome, Inc. Selected As Metagenics Inc. Provider For Seres Health Clinical Trial 10/27/2014
Clementia Announces Open-Label Phase 2 Extension Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva 10/27/2014
Verastem, Inc. (VSTM) Presents New Data On Mesothelioma Programs At The 12th International Mesothelioma Interest Group Meeting 10/24/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In Lucitanib Phase 2 Study In Squamous Non-small Cell Lung Cancer 10/24/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS – FDA Response To Phase 2b Study Plans 10/24/2014
ALS ACT, The ALS Association, And The Northeast ALS Consortium Issue Request For Proposals For Phase 2 Clinical Development Of Novel, High-Potential Treatments For ALS 10/24/2014
Rhythm Presents Positive Phase 2 Study Results For Relamorelin For Chronic Constipation 10/24/2014
Synageva BioPharma (GEVA) Presents Sebelipase Alfa Data At The NASPGHAN Meeting 10/24/2014
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014
MediciNova, Inc. Announces FDA Granted Orphan Drug Designation To MN-001 (Tipelukast) For Idiopathic Pulmonary Fibrosis (IPF) 10/23/2014
SAGE Therapeutics Initiates Exploratory Study Of SAGE-547 In Essential Tremor 10/23/2014
NeuralStem Inc. Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting 10/23/2014
Islet Sciences And BHV Announce Publication Of Two Phase 2b Clinical Studies Of Remogliflozin Etabonate For Treating Type 2 Diabetes 10/23/2014
Cellceutix (CTIX) Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable To 7-Days Of Daptomycin 10/23/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Positive Top-Line Data From U.S. Phase 2a Trial With Oral Insulin In Type 1 Diabetes 10/22/2014
Nuvo Research Inc. (NRI.TO) Completes WF10™ U.S. Market Study For Treatment Of Refractory Allergies 10/22/2014
Immunomedics, Inc. (IMMU) To Present Updated Clinical Results With Solid-Tumor Antibody-Drug Conjugates At Upcoming Conferences 10/22/2014
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Designation From European Medicines Agency For The Treatment Of Dravet Syndrome 10/22/2014
Regulus Therapeutics, Inc. (RGLS) Gets Seat At Hepatitis C Table With Impressive Phase 1 Results 10/22/2014
Maxwell Biotech Portfolio Company Hepatera Announces Proof-Of-Concept Clinical Results With Myrcludex B, A Novel Entry Inhibitor For Treatment Of Chronic Hepatitis B And Delta 10/21/2014
TWi Biotechnology Receives Orphan Drug Designation For Its Lead Drug Candidate AC-201 In United States 10/21/2014
Generex Biotechnology Corporation (GNBT) Announces Publication Of Ebola Vaccine White Paper By Antigen Express, Inc. (GNBT) 10/21/2014
Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 10/21/2014
Hatchtech Announces Successful Results From Phase 2 Ovicidal Study 10/21/2014
CytRx Corporation (CYTR) Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society 10/20/2014
Immunomedics, Inc. (IMMU) Announces European Orphan Drug Designation For Isactuzumab Govitecan For Pancreatic Cancer Treatment 10/20/2014
Norgine Release: Positive Results From Phase 2 Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 10/20/2014
Milo Biotechnology's Follistatin Gene Therapy Increases Function In Becker Muscular Dystrophy Patients 10/20/2014
Genervon Announces ALS And PD Phase 2a Trial Results 10/20/2014
CytRx Corporation (CYTR) To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting 10/17/2014
Deltanoid Pharmaceuticals, Inc.'s DP001 (2MD) Pharmaceutical Demonstrated Safe And Effective In Kidney Failure Patients On Dialysis 10/16/2014
Chimerix, Inc. (CMRX) Provides Update On Research and Development Progress; FDA OKs Brincidofovir In Phase 2 For Ebola Virus Disease 10/16/2014
ContraVir Pharmaceuticals Selects Pharmaceutical Product Development To Manage Phase 2b Study Of Lead Antiviral FV-100 For Treating Shingles 10/16/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
Amarantus BioSciences, Inc. Applies To FDA For MANF Orphan Drug Designation In Retinitis Pigmentosa 10/16/2014
Ironwood Pharmaceuticals (IRWD) Announces Initiation Of Phase 2 Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation 10/16/2014



//-->